Heading to the stars in RAS driven cancers
Hubble image, as seen at the Hamburg Planetarium
If you visit your local Planetarium, you’ll notice the night sky and how both the brightness and closeness of stars are constantly changing with the seasons and orbits of planets.
Like oncology drug development, it’s a dynamic, constantly moving environment.
Some companies shine brightly for a while then fizzle out, others take a while to show up in the night sky depending on which direction observers are looking in.
In this post we’re taking a closer look at an early stage biotech with an innovative approach to targeting KRAS. Will it be a future star?
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
